Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 392, Issue 2, pp 199–208 | Cite as

Hydrolysis of the non-canonical cyclic nucleotide cUMP by PDE9A: kinetics and binding mode

  • Jessica Scharrenbroich
  • Volkhard Kaever
  • Stefan Dove
  • Roland Seifert
  • Erich H. SchneiderEmail author
Original Article
  • 73 Downloads

Abstract

The non-canonical cyclic nucleotide cUMP and the phosphodiesterase PDE9A both occur in neuronal cells. Using HPLC-coupled tandem mass spectrometry, we characterized the kinetics of PDE9A-mediated cUMP hydrolysis. PDE9A is a low-affinity and high-velocity enzyme for cUMP (Vmax = ~ 6 μmol/min/mg; Km = ~ 401 μM). The PDE9 inhibitor BAY 73-6691 inhibited PDE9A-catalyzed cUMP hydrolysis (Ki = 590 nM). Docking studies indicate two H-bonds between the cUMP uridine moiety and Gln453/Asn405 of PDE9A. By contrast, the guanosine moiety of cGMP forms three H-bonds with Gln453. cCMP is not hydrolyzed at a concentration of 3 μM, but inhibits the PDE9A-catalyzed cUMP hydrolysis at concentrations of 100 μM or more. The probable main reason is that the cytosine moiety cannot act as H-bond acceptor for Gln453. A comparison of PDE9A with PDE7A suggests that the preference of the former for cGMP and cUMP and of the latter for cAMP and cCMP is due to stabilized alternative conformations of the side chain amide of Gln453 and Gln413, respectively. This so-called glutamine switch is known to be involved in the regulation of cAMP/cGMP selectivity of some PDEs.

Keywords

Cyclic UMP Cyclic CMP Phosphodiesterase PDE9A Enzyme kinetics Glutamine switch 

Abbreviations

BSA

Bovine serum albumin

cAMP

Adenosine 3′,5′-cyclic monophosphate

cCMP

Cytidine 3′,5′-cyclic monophosphate

cGMP

Guanosine 3′,5′-cyclic monophosphate

CMP

Cytidine 5′-monophosphate

cNMP

Nucleoside 3′,5′-cyclic monophosphate

cUMP

Uridine 3′,5′-cyclic monophosphate

EDTA

Ethylenediaminetetraacetic acid

ExoY

Exotoxin of Pseudomonas aeruginosa with nucleotidyl cyclase properties

GMP

Guanosine 5′-monophosphate

GST

Glutathione S-transferase (used as protein tag)

HCN

Hyperpolarization-activated cyclic nucleotide-gated channel

HPLC-MS/MS

High-performance liquid chromatography-coupled tandem mass spectrometry

IBMX

3-Isobutyl-1-methylxanthine

Km

Michaelis-Menten constant

MRP

Multidrug resistance-associated protein

NMP

Nucleoside 5′-monophosphate

PDE

Phosphodiesterase

PKA

Protein kinase A

PKG

Protein kinase G

sAC

Soluble adenylyl cyclase

SD

Standard deviation

SEM

Standard error of the mean

sGC

Soluble guanylyl cyclase

UMP

Uridine 5′-monophosphate

Vmax

Maximum velocity of an enzymatic reaction under saturating conditions

Notes

Acknowledgements

We thank Prof. Dr. Martin Stangel (Dept. of Clinical Neuroimmunology and Neurochemistry, MHH) and Dr. Sabine Wolter (Institute of Pharmacology, MHH) for the excellent scientific discussions as well as Mrs. Annette Garbe (Research Core Unit Metabolomics, MHH) for the outstanding technical support.

Author contributions

Participated in research design: Schneider, Scharrenbroich, Seifert

Conducted experiments: Scharrenbroich, Kaever

Performed data analysis: Scharrenbroich, Schneider

Performed docking approaches: Dove

Wrote or contributed to the writing of the manuscript: Scharrenbroich, Schneider, Dove, Kaever, Seifert

References

  1. Beckert U, Grundmann M, Wolter S, Schwede F, Rehmann H, Kaever V, Kostenis E, Seifert R (2014a) cNMP-AMs mimic and dissect bacterial nucleotidyl cyclase toxin effects. Biochem Biophys Res Commun 451:497–502CrossRefGoogle Scholar
  2. Beckert U, Wolter S, Hartwig C, Bähre H, Kaever V, Ladant D, Frank DW, Seifert R (2014b) ExoY from Pseudomonas aeruginosa is a nucleotidyl cyclase with preference for cGMP and cUMP formation. Biochem Biophys Res Commun 450:870–874CrossRefGoogle Scholar
  3. Bellamy TC, Garthwaite J (2001) “cAMP-specific” phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide. Mol Pharmacol 59:54–61CrossRefGoogle Scholar
  4. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520CrossRefGoogle Scholar
  5. Berrisch S, Ostermeyer J, Kaever V, Kälble S, Hilfiker-Kleiner D, Seifert R, Schneider EH (2017) cUMP hydrolysis by PDE3A. Naunyn Schmiedeberg’s Arch Pharmacol 390:269–280CrossRefGoogle Scholar
  6. Brus R, Herman ZS, Juraszczyk Z, Krzemiński T, Trzeciak H, Kurcok A (1984) Central action of cyclic: 3′,5′-thymidine, 3′,5′-uridine and 3′,5′-citidine monophosphates in rat. Acta Med Pol 25:1–9Google Scholar
  7. Bähre H, Danker KY, Stasch JP, Kaever V, Seifert R (2014) Nucleotidyl cyclase activity of soluble guanylyl cyclase in intact cells. Biochem Biophys Res Commun 443:1195–1199CrossRefGoogle Scholar
  8. Bähre H, Hartwig C, Munder A, Wolter S, Stelzer T, Schirmer B, Beckert U, Frank DW, Tümmler B, Kaever V, Seifert R (2015) cCMP and cUMP occur in vivo. Biochem Biophys Res Commun 460:909–914CrossRefGoogle Scholar
  9. Chen J, Martinez J, Milner TA, Buck J, Levin LR (2013) Neuronal expression of soluble adenylyl cyclase in the mammalian brain. Brain Res 1518(1–8):1–8CrossRefGoogle Scholar
  10. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108CrossRefGoogle Scholar
  11. Cheung WY (1967) Properties of cyclic 3′,5′-nucleotide phosphodiesterase from rat brain. Biochemistry 6:1079–1087CrossRefGoogle Scholar
  12. Choi HB, Gordon GR, Zhou N, Tai C, Rungta RL, Martinez J, Milner TA, Ryu JK, McLarnon JG, Tresguerres M, Levin LR, Buck J, MacVicar BA (2012) Metabolic communication between astrocytes and neurons via bicarbonate-responsive soluble adenylyl cyclase. Neuron 75:1094–1104CrossRefGoogle Scholar
  13. Clark M, Cramer RDI, Van Opdenbosch N (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982–1012CrossRefGoogle Scholar
  14. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179–5197CrossRefGoogle Scholar
  15. Drummond GI, Perrott-Yee S (1961) Enzymatic hydrolysis of adenosine 3′,5′-phosphoric acid. J Biol Chem 236:1126–1129Google Scholar
  16. Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB (1998) Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559–15564CrossRefGoogle Scholar
  17. Hartwig C, Bähre H, Wolter S, Beckert U, Kaever V, Seifert R (2014) cAMP, cGMP, cCMP and cUMP concentrations across the tree of life: high cCMP and cUMP levels in astrocytes. Neurosci Lett 579:183–187CrossRefGoogle Scholar
  18. Hasan A, Danker KY, Wolter S, Bähre H, Kaever V, Seifert R (2014) Soluble adenylyl cyclase accounts for high basal cCMP and cUMP concentrations in HEK293 and B103 cells. Biochem Biophys Res Commun 448:236–240CrossRefGoogle Scholar
  19. Laue S, Winterhoff M, Kaever V, van den Heuvel JJ, Russel FG, Seifert R (2014) cCMP is a substrate for MRP5. Naunyn Schmiedeberg's Arch Pharmacol 387:893–895CrossRefGoogle Scholar
  20. Liu S, Mansour MN, Dillman KS, Perez JR, Danley DE, Aeed PA, Simons SP, Lemotte PK, Menniti FS (2008) Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proc Natl Acad Sci U S A 105:13309–13314CrossRefGoogle Scholar
  21. Monzel M, Kuhn M, Bähre H, Seifert R, Schneider EH (2014) PDE7A1 hydrolyzes cCMP. FEBS Lett 588:3469–3474CrossRefGoogle Scholar
  22. Munder A, Rothschuh J, Schirmer B, Klockgether J, Kaever V, Tümmler B, Seifert R, Kloth C (2018) The Pseudomonas aeruginosa ExoY phenotype of high-copy-number recombinants is not detectable in natural isolates. Open Biol 8:170250CrossRefGoogle Scholar
  23. Ostermeyer J, Golly F, Kaever V, Dove S, Seifert R, Schneider EH (2018) cUMP hydrolysis by PDE3B. Naunyn Schmiedebergs Arch Pharmacol 391:891–905.  https://doi.org/10.1007/s00210-00018-01512-00216 CrossRefGoogle Scholar
  24. Reinecke D, Burhenne H, Sandner P, Kaever V, Seifert R (2011) Human cyclic nucleotide phosphodiesterases possess a much broader substrate-specificity than previously appreciated. FEBS Lett 585:3259–3262CrossRefGoogle Scholar
  25. Seifert R, Schneider EH, Bähre H (2015) From canonical to non-canonical cyclic nucleotides as second messengers: pharmacological implications. Pharmacol Ther 148:154–184CrossRefGoogle Scholar
  26. Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553–15558CrossRefGoogle Scholar
  27. van der Staay FJ, Rutten K, Bärfacker L, Devry J, Erb C, Heckroth H, Karthaus D, Tersteegen A, van Kampen M, Blokland A, Prickaerts J, Reymann KG, Schröder UH, Hendrix M (2008) The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 55:908–918CrossRefGoogle Scholar
  28. van Staveren WC, Glick J, Markerink-van Ittersum M, Shimizu M, Beavo JA, Steinbusch HW, de Vente J (2002) Cloning and localization of the cGMP-specific phosphodiesterase type 9 in the rat brain. J Neurocytol 31:729–741CrossRefGoogle Scholar
  29. Vecsler M, Lazar I, Tzur A (2013) Using standard optical flow cytometry for synchronizing proliferating cells in the G1 phase. PLoS One 8:e83935CrossRefGoogle Scholar
  30. Wang H, Liu Y, Chen Y, Robinson H, Ke H (2005) Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 280:30949–30955CrossRefGoogle Scholar
  31. Wang H, Liu Y, Hou J, Zheng M, Robinson H, Ke H (2007a) Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci U S A 104:5782–5787CrossRefGoogle Scholar
  32. Wang H, Robinson H, Ke H (2007b) The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J Mol Biol 371:302–307CrossRefGoogle Scholar
  33. Wolter S, Golombek M, Seifert R (2011) Differential activation of cAMP- and cGMP-dependent protein kinases by cyclic purine and pyrimidine nucleotides. Biochem Biophys Res Commun 415:563–566CrossRefGoogle Scholar
  34. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68:1775–1781Google Scholar
  35. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, Bollag G (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15:279–286CrossRefGoogle Scholar
  36. Zong X, Krause S, Chen CC, Krüger J, Gruner C, Cao-Ehlker X, Fenske S, Wahl-Schott C, Biel M (2012) Regulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity by cCMP. J Biol Chem 287:26506–26512CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Hannover Medical SchoolInstitute of PharmacologyHannoverGermany
  2. 2.Research Core Unit Metabolomics, Hannover Medical SchoolInstitute of PharmacologyHannoverGermany
  3. 3.Department of Medicinal Chemistry II, Institute of PharmacyUniversity of RegensburgRegensburgGermany

Personalised recommendations